Study of DCR-PHXC-101 in Normal Healthy Volunteers and Patients With Primary Hyperoxaluria

A Placebo-Controlled, Single-Blind, Single-Center Phase 1 Study in Normal Healthy Volunteers and Open-Label Multi-Center Study in Patients With Primary Hyperoxaluria to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Single Ascending Doses of DCR-PHXC Solution for Injection (Subcutaneous Use)

This is a double-blind, placebo-controlled, dose escalation trial of DCR-PHXC in Healthy Volunteers (HVs) and patients with Primary Hyperoxaluria (PH). Once safety has been established in HV, PH patients with a confirmed diagnosis of PH1 and PH2 will be enrolled across multiple dosing cohorts. The study design will allow enrollment of PH patient cohorts at a given dose level once safety has been demonstrated in HV at that dose level. The study will be conducted in two parts: Part A: Single ascending dose (SAD) in HV; Part B: SAD in patients with PH1 and PH2 (lagging Part A by 1 dose level cohort).

Study Overview

• Status: Completed
• Conditions: Primary Hyperoxaluria
• Intervention / Treatment: Drug: DCR-PHXC; Drug: Placebo

• Study Type: Interventional
• Enrollment (Actual): 43
• Phase: Phase 1

Contacts and Locations

Study Locations

• France
  • Bron, France, 69677
    • Centre d'Investigation Clinique - CIC 1407 - Hospices Civils de Lyon
• Germany
  • Bonn, Germany, 53127
    • Universitätsklinikum Bonn-Institut für Klinische Chemie und Klinische Pharmakologie
• Netherlands
  • Amsterdam, Netherlands, 1012 WX
    • University of Amsterdam
• United Kingdom
  • Birmingham, United Kingdom, B15 2GW
    • Queen Elizabeth Hospital Birmingham
  • Birmingham, United Kingdom, B4 6NH
    • Birmingham Children's Hospital NHS Trust
  • Wales, United Kingdom, CF484DR
    • Clinical Trial Site
• United States
  • Massachusetts
    • Boston, Massachusetts, United States, 02115
      • Boston Children's Hospital

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: 6 years and older (Child, Adult, Older Adult)
• Accepts Healthy Volunteers: No
• Genders Eligible for Study: All

Description

Group A (HVs) Major Inclusion Criteria:

• Willing and able to provide informed consent and comply with study requirements.
• Male or female subjects between 18 and 55 years of age, inclusive.
• Subject must have a body mass index (BMI) 19.0 to 32 kg/m2, inclusive.
• Non-smokers, at least 1-month tobacco free, and willing to remain tobacco free through end of study (EOS).
• Women of child bearing potential must have a negative pregnancy test, cannot be breastfeeding, and must be willing to use contraception.

Group A (HVs) Major Exclusion Criteria:

• Presence of any medical condition, including but not limited to: Severe intercurrent illness, known causes of active liver disease.
• Routine or chronic use of more than 3 grams of acetaminophen (Tylenol) daily.
• History of kidney stones.
• Use of any investigational agent within 90 days before the first dose of study medication.
• History of donation of more than 450 mL of blood within 90 days prior to dosing in the clinical research center or planned donation less than 30 days after receiving Investigational Medicinal Product (IMP).
• Plasma or platelet donation within 7 days of dosing and through EOS.
• History of reactions to an oligonucleotide-based therapy.
• Males with female partners who are planning to attempt to become pregnant during this study or within 90 days after last dosing of IMP.
• Plasma or platelet donation within 7 days of dosing and through EOS.

Group B (PH1 and PH2 patients) Major Inclusion Criteria:

• Willing and able to provide informed consent and comply with study requirements.
• Male or female, at least 6 years of age.
• Minimum body weight of 25 kg.
• Genetic confirmation of PH1 and PH2 disease.
• Meet the 24 hour urine oxalate excretion requirements.
• Estimated glomerular filtration rate (eGFR) ≥30 mL/min/1.73 m2.
• If taking Vitamin B6 (pyridoxine), must have been on stable regimen for at least 4 weeks.

Group B (PH1 and PH2 patients) Major Exclusion Criteria:

• Prior renal and/or hepatic transplantation.
• Currently receiving dialysis.
• Participation in any clinical study where they received an investigational agent within 4 months before enrollment.
• Presence of any medical condition, including but not limited to: Severe intercurrent illness, known causes of active liver disease.
• Liver function test (LFT) abnormalities.
• History of reactions to an oligonucleotide-based therapy.

Study Plan

How is the study designed?

Design Details

• Primary Purpose: Treatment
• Allocation: Randomized
• Interventional Model: Parallel Assignment
• Masking: Double

Number of Arms

3

Arms and Interventions

Participant Group / Arm	Intervention / Treatment
Experimental: Group A Active (DCR-PHXC); HVs, single ascending doses of DCR-PHXC.	Drug: DCR-PHXC; DCR-PHXC is a novel, potent, and long-acting small interference ribonucleic acid (siRNA) molecule conjugated to N-acteylgalactosamine (GalNAc) that is designed to decrease liver oxalate production. DCR-PHXC is delivered via subcutaneous (SC) injection.
Placebo Comparator: Group A Placebo; HVs, normal saline 0.9% injection to match active doses.	Drug: Placebo; Single SC administration of placebo, which will be a sterile, preservative-free normal saline 0.9% solution for SC injection, which is of similar osmolality to the DCR-PHXC formulation.
Experimental: Group B Active (DCR-PHXC); PH1 and PH2 patients, open label, single ascending doses of DCR-PHXC.	Drug: DCR-PHXC; DCR-PHXC is a novel, potent, and long-acting small interference ribonucleic acid (siRNA) molecule conjugated to N-acteylgalactosamine (GalNAc) that is designed to decrease liver oxalate production. DCR-PHXC is delivered via subcutaneous (SC) injection.

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Time Frame
Number of patients with Treatment-Related Adverse Events (TEAEs)	Part A (SAD in HVs) screening through Day 29; Part B (SAD in PH patients) screening through Day 57

Collaborators and Investigators

• Sponsor: Dicerna Pharmaceuticals, Inc.

Study record dates

Study Major Dates

• Study Start (Actual): December 6, 2017
• Primary Completion (Actual): November 19, 2019
• Study Completion (Actual): November 19, 2019

Study Registration Dates

• First Submitted: December 21, 2017
• First Submitted That Met QC Criteria: January 2, 2018
• First Posted (Actual): January 8, 2018

Study Record Updates

• Last Update Posted (Actual): January 22, 2020
• Last Update Submitted That Met QC Criteria: January 17, 2020
• Last Verified: January 1, 2020

More Information

Terms related to this study

• Additional Relevant MeSH Terms: Metabolic Diseases; Kidney Diseases; Urologic Diseases; Genetic Diseases, Inborn; Carbohydrate Metabolism, Inborn Errors; Metabolism, Inborn Errors; Hyperoxaluria; Hyperoxaluria, Primary
• Other Study ID Numbers: DCR-PHXC-101

Plan for Individual participant data (IPD)

• Plan to Share Individual Participant Data (IPD)?: No

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: Yes
• Studies a U.S. FDA-regulated device product: No
• product manufactured in and exported from the U.S.: Yes